Scientific prerequisites and prospects for the use of sildenafil in patients with COVID-19
- Authors: Tsvetov V.M1, Matveev A.V2
-
Affiliations:
- Federal Center for Cardiovascular Surgery
- Russian Medical Academy of Continuous Professional Education
- Issue: Vol 28, No 2 (2021)
- Pages: 12-14
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/313074
- DOI: https://doi.org/10.18565/pharmateca.2021.2.12-14
- ID: 313074
Cite item
Open Access
Access granted
Abstract
Currently, there are only theoretical prerequisites for using the sildenafil to treat patients with COVID-19. There is no clinical evidence to recommend the use of this drug in real clinical practice to prevent and alleviate symptoms in patients with COVID-19. The use of sildenafil in the treatment of a new coronavirus infection is possible only within the framework of clinical trials.
Keywords
Full Text
About the authors
V. M Tsvetov
Federal Center for Cardiovascular SurgeryChelyabinsk, Russia
A. V Matveev
Russian Medical Academy of Continuous Professional EducationMoscow, Russia
References
- Государственный реестр лекарственных средств (Электронный ресурс). [State Register of Medicines (Electronic resource). (In Russ.)]. URL: http://grls.rosminzdrav.ru/Grls_ View_ v2.aspx?routingGuid=88e3ecde-ddbc-4f04-99bc-e4419c9bd4c7&t=.
- Limodio M, et al. Hypothesis of COVID-19 Therapy with Sildenafil. Int J Prev Med. 2020;11:76. Doi: 10.4103/ ijpvm.IJPVM_258_20.
- Государственный реестр лекарственных средств (Электронный ресурс). [State Register of Medicines (Electronic resource). (In Russ.)]. URL: http://grls.rosminzdrav.ru/Grls_ View_ v2.aspx?routing Guid=cb3ec347-bdc9-403f-b07b-158a9f23084e&t=
- EU Clinical Trials Register [Electronic resource]. URL: https://clinicaltrials.gov/ct2/results?cond=Co vid19&te rm=&type=&rslt=&age_v=&gndr=&intr=Sildenafil
- The National Center for Biotechnology Information advances science and health by providing access to biomedical and genomic information [Electronic resource]. URL: https://pubmed.ncbi.nlm.nih.gov/?ter m=covid+19+and+sildenafil
- Isidori A.M., et al. Targeting the NO-cGMP-PDE5 pathway in COVID-19 infection. The DEDALO project. Andrology 2021;9(1):33-8. doi: 10.1111/and. 12837.
- Dal Moro F., et al. The war against the SARS-CoV2 infection: Is it better to fight or mitigate it? Med. Hypotheses. 2020;143:110129. Doi: 10.1016/j. mehy.2020. 110129.
- Shirvaliloo M. Targeting the SARS-CoV-2 3CLpn} and NO/ cGMP/PDE5 pathway in COVID-19: a commentary on PDE5 inhibitors. Future Cardiol. 2021 Feb 12;10.2217/ fca-2020-0201. doi: 10.2217/fca-2020-0201.
- Hutchings D.C., Anderson S.G., Caldwell J.L., Trafford A.W. Phosphodiesterase-5 inhibitors and the heart: compound cardioprotection? Heart. 2018;104(15):1244-50. Doi: 10.1136/ heartjnl-2017-312865.
- Giannetta E., Isidori A.M., Galea N., et al. Chronic inhibition of cGMP phosphodiesterase 5A improves diabetic cardiomyopathy: a randomized, controlled clinical trial using magnetic resonance imaging with myocardial tagging. Circulation. 2012;125(19):2323-33. doi: 10.1161/CIRCULATIONAHA.111.063412.
- Wu R., Wang L., Kuo H.C.D., et al. An update on current therapeutic drugs treating COVID-19. Curr Pharmacol Reports. 2020;6(3):56-70. doi: 10.1007/s40495-020-00216-7.
- Mario L., Roberto M., Marta L., et al. Hypothesis of COVID-19 therapy with sildenafil. Int J Prev Med.
- Qiao Z., Zhang H., Ji H.F., Chen Q. Computational view toward the inhibition of SARS-CoV-2 spike glycoprotein and the 3CL protease. Computation. 2020;8(2):53. doi: 10.3390/computation8020053.
- Временные методические рекомендации. Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19). 7-е изд., М., 2020. 261 c.
- Giuliano F., Jackson G., Montorsi F., et al. Safety of sildenafil citrate: review of 67 double-blind placebo-controlled trials and the postmarketing safety database. Int J Clin Pract. 2010;64(2):240-55. doi: 10.1111/j.1742-1241.2009.02254.x.
- Laties A., Sharlip I. Ocular safety in patients using sildenafil citrate therapy for erectile dysfunction. J Sex Med. 2006;3(1):12-27. doi: 10.1111/j.1743-6109.2005.00194.x.
- Blonde L. Sildenafil citrate for erectile dysfunction in men with diabetes and cardiovascular risk factors: a retrospective analysis of pooled data from placebo-controlledtrials. CurrMedResOpin. 2006;22(11):2111-20. doi: 10.1185/030079906X148256.
Supplementary files
